Introduction: Navigating the Complex Landscape of ADHD Care
Attention-deficit/hyperactivity disorder (ADHD) is no longer viewed strictly as a pediatric condition. With a global prevalence of approximately 5 percent in children and 2.5 percent in adults, the management of ADHD requires a longitudinal perspective that spans the entire lifespan. Despite the abundance of clinical trials and systematic reviews, clinicians and patients often struggle with conflicting data regarding the comparative efficacy, tolerability, and long-term safety of pharmacological and non-pharmacological interventions.
A landmark study published in the BMJ, titled Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making (Gosling et al., 2025), addresses these challenges head-on. By synthesizing data from hundreds of meta-analyses and developing a living evidence platform, the researchers provide a robust framework for evidence-based practice and shared decision-making (SDM).
